FDA hair testing policy
This article was originally published in The Gray Sheet
Executive Summary
Agency formally revokes 1990 compliance policy guide requiring PMA submissions for all radioimmunoassay drugs-of-abuse hair tests in a Jan. 5 Federal Register notice. The tests now require premarket notification, a position consistent with their inclusion in FDA's Dec. 1 DoA testing premarket submission draft guidance designed to clarify the 510(k) process for such products (1"The Gray Sheet" Dec. 8, 2003, p. 12)...
You may also be interested in...
Flexible Approach Granted For Drugs-Of-Abuse Premarket Submissions
FDA's decision to allow alternatives to bundling confirmatory test costs with initial screening costs reflects greater flexibility in the agency's approach to premarket requirements for drugs-of-abuse tests, according to FDA
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.